Table 3—

Haemodynamic measurement before (I) and during (II) therapy with epoprostenol

PatientmPAP I mmHgmPAP II mmHgCardiac index I L·min−1·m−2Cardiac index II L·min−1·m−2PVR/TPR I dyn·s−1·cm−5PVR/TPR II dyn−1·s−1·cm−5
Clinical stability
 A102/35 (59)69/22 (40)2.12.91168/1349633/667
 B78/30 (48)72/27 (45)2.12.6665/873593/667
 C69/28 (41)77/29 (48)1.51.9704/993705/914
Clinical improvement
 D62/26 (42)65/30 (42)0.91.8914/1600720/840
 E129/38 (68)87/36 (53)0.91.3ND/30221323/1631
 F118/46 (77)95/15 (50)2.42.21172/1432760/1000
Clinical progression
 G78/27 (46)91/45 (61)1.51.7933/12261236/1469
 H108/29 (56)78/28 (46)1.62.01128/1445978/1022
 I83/32 (54)81/40 (55)1.21.11376/17281628/1913
  • mPAP: mean pulmonary artery pressure

  • PVR: pulmonary vascular resistance

  • TPR: total pulmonary resistance

  • ND: not determined